Publication of Clinical Trial Results. Celgene will have the right to publish summaries of results of all Clinical Trials conducted by either Party with respect to a Licensed Product incorporating a Celgene Development Compound or, to the extent required by Law, GlobeImmune Development Compound after the Effective Date on Celgene’s Clinical Trial register; provided, however, that GlobeImmune will have the right to review all proposed publications relating to a GlobeImmune Development Compound prior to submission of such publication. The Parties shall discuss and reasonably cooperate in order to facilitate the process to be employed in order to ensure the publication of any such summaries of Clinical Trials data and results as required on the Clinical Trial registry of each respective Party, and shall provide the other Party at least forty-five (45) days prior notice to review the Clinical Trials results to be published for the purposes of preparing any necessary Patent filings. Notwithstanding anything to the contrary in this Section 9.7.3, GlobeImmune’s clinical trial sites shall have the right to publish summaries of results of Clinical Trials conducted by GlobeImmune at such site with respect to a Licensed Product incorporating a Collaboration Compound to the extent required under the applicable agreement(s) between GlobeImmune and such clinical trial sites.
Publication of Clinical Trial Results. Takeda will have the right to publish summaries of results of all Clinical Trials conducted by either Party with respect to a Product after the Effective Date in Takeda’s Clinical Trial register; provided, however, that Orexigen will have the right to review all proposed publications prior to submission of such publication. The Parties shall discuss and reasonably cooperate in order to facilitate the process to be employed in order to ensure the publication of any such summaries of Clinical Trials data and results as required under Laws on the Clinical Trial registry of each respective Party, and shall provide the other Party at least [***] ([***]) days prior notice to review the Clinical Trials results to be published for the purposes of preparing any necessary Patent filings.
Publication of Clinical Trial Results. Scholar Rock agrees that, after exercise of the License Option for Collaboration Molecules and/or Lead Molecules with a specific Pharmacological Profile, JBI and/or its Affiliates shall be permitted to disclose Scholar Rock Confidential Information related thereto in publishing clinical trial results in accordance with any applicable FDA and EMA guidelines and in accordance with Xxxxxxx & Xxxxxxx clinical trial publication policy.
Publication of Clinical Trial Results. GSK will have the right to publish summaries of results of all Clinical Trials conducted by GSK with respect to a Product or Combination Product incorporating a GSK Development Compound on GSK’s Clinical Trial register; provided, however, that GSK will use reasonable effort to provide such summaries to OncoMed at least [***] prior to publishing such summaries for the purposes of preparing any necessary Patent filings. It is understood that the Parties will collaborate to ensure that the data is reviewed to ensure adequate patent protection is obtained in advance of publication of such data.
Publication of Clinical Trial Results. Notwithstanding anything to the contrary in Article 8, Avanir may publish any data within the Concert Technology, Collaboration Technology or otherwise resulting from Clinical Trials conducted on a Licensed Product, subject to the JSC’s review and approval of all such proposed publications before First IND, and thereafter in Avanir’s discretion without review by the JSC or Concert. Avanir shall send a draft manuscript of any such publication proposed to be published before the First IND of a Licensed Product by FDA or EMA to Concert for review at least [**] days before the date on which Avanir plans to submit the proposed submission for publication, and as to any such proposed publications before First IND Concert may provide comments thereon to Avanir. If Concert has any comments as to any such proposed publications before First IND, Concert shall provide its written comment on the publication within [**] days from receipt of the draft. Avanir shall, to the extent permitted under applicable Laws, reasonably consider all such comments from Concert as to any such proposed publications. Any dispute over any such proposed publications shall be resolved by the chairperson of the JSC.
Publication of Clinical Trial Results. Notwithstanding anything to the contrary in this Article, OPI may publish any data within the Licensed Technology or otherwise resulting from Clinical Trials conducted on a Licensed Product without consent of either Licensor.
Publication of Clinical Trial Results. Takeda will have the right to publish summaries of results of all Clinical Trials conducted by either Party with respect to a Product after the Original Effective Date in Takeda’s Clinical Trial register; provided, however, that Orexigen will have the right to review all proposed publications prior to submission of such publication. The Parties shall discuss and reasonably cooperate in order to facilitate the process to be employed in order to ensure the publication of any such summaries of Clinical Trials data and results as required under Laws on the Clinical Trial registry of each respective Party, and shall provide the other Party at least sixty (60) days prior notice to review the Clinical Trials results to be published for the purposes of preparing any necessary Patent filings.
Publication of Clinical Trial Results. For any Clinical Study under this Agreement, the Parties agree to collaborate to publish the results of such studies and agree that they will not independently publish, publicly disclose, present or discuss any results of or information pertaining to the Clinical Study until a joint publication is released; provided however, that if a Party desires to withdraw from it participation in a joint publication, then the other Party will have the right to publish the Clinical Study results in accordance with the provisions of this section (the “Publishing Party”). The requirements of this Section 5.6 apply to all abstracts, articles, manuscripts, presentations and other forms of publication regarding the results of activities performed pursuant to such studies or trials (collectively, “Publications”). Unless the Publication is jointly authored by the Parties, the Publishing Party will provide to the other Party a copy of the Publication for review to determine whether Confidential Information is disclosed, to allow the other Party to protect its rights in patentable or copyrightable materials, and to check for technical correctness. When requested by the other Party, the Publishing Party will delay publication up to an additional forty-five (45) days to allow the other Party to protect its right in patentable or copyrightable material. If notified by the other Party within the forty five (45) day review period that such Publication contains Confidential Information, the Publishing Party shall delete Confidential Information and the Parties shall come to a mutual agreement upon any other technical and editorial corrections requested by the other Party prior to publication or presentation. Nile acknowledges that, per Medtronic’s policy, Medtronic will not compensate Nile or any Healthcare Professional (as defined below) who serve as authors or contributors on Publications for their writing or editing activities. Nile agrees that any fees or costs related to Publication writing or editing activities are not included in the Budget set forth in Exhibit B. “Healthcare Professional” means any person, other than an individual patient, in a position to purchase, lease, recommend, use, influence or arrange for the purchase or lease of, or prescribe Medtronic products. Healthcare Professionals include, but are not limited to, physicians, nurses, nurse practitioners, physician assistants, clinical PharmDs, clinical psychologists, dentists, and surgeons.
Publication of Clinical Trial Results. In connection with the licenses hereunder, XxxxxXxxx agrees that it will, and it will cause any of its Affiliates to agree to, permit Pulmatrix and its Affiliates to register and publish Development data as required by law or industry best practices, and otherwise comply with all terms therein, notwithstanding the provisions of Sections 6.1 and 6.3.
Publication of Clinical Trial Results. Unless otherwise agreed in writing, the Parties agree that JBI shall have the right to disclose: (i) each clinical trial conducted pursuant to the IND Submission and Manufacturing Update Plan on xxxxxxxxxxxxxx.xxx or any other similar registry, and (ii) all results of such clinical trial on xxxxxxxxxxxxxxxxxxxx.xxx and on any other registry with requirements consistent with the registration and publication guidelines of the International Committee of Medical Journal Editors, to the extent required.
